CR20110031A - NUEVOS DERIVADOS DE IMIDAZO [1,2-a]PIRIMIDINA, SU PROCEDIMIENTO DE PREPARACIÓN, SU APLICACIÓN COMO MEDICAMENTOS, COMPOSICIONES FARMACÉUTICAS Y NUEVA UTILIZACIÓN PARTICULARMENTE COMO INHIBIDORES DE MET - Google Patents

NUEVOS DERIVADOS DE IMIDAZO [1,2-a]PIRIMIDINA, SU PROCEDIMIENTO DE PREPARACIÓN, SU APLICACIÓN COMO MEDICAMENTOS, COMPOSICIONES FARMACÉUTICAS Y NUEVA UTILIZACIÓN PARTICULARMENTE COMO INHIBIDORES DE MET

Info

Publication number
CR20110031A
CR20110031A CR20110031A CR20110031A CR20110031A CR 20110031 A CR20110031 A CR 20110031A CR 20110031 A CR20110031 A CR 20110031A CR 20110031 A CR20110031 A CR 20110031A CR 20110031 A CR20110031 A CR 20110031A
Authority
CR
Costa Rica
Prior art keywords
new
pyrimidine
medicines
pharmaceutical compositions
application
Prior art date
Application number
CR20110031A
Other languages
English (en)
Inventor
Eric Bacque
Dominique Damour
Conception Nemecek
Patrick Nemecek
Laurent Schio
Sylvie Wentzler
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40352183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110031(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CR20110031A publication Critical patent/CR20110031A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a los productos nuevos de fórmula (I): en la que:n =0,1 ó 2; x representa H, Hal o alk; R representa H, NH2, NHalk, N(alk)2; Ra representa H; Hal; -O-cicloalquilo; -O-alquilo, -O-arilo; -O-heteroarilo; -NRd(cicloalquilo); -NRd(alquilo); -NRd(arilo); -NRd(heteroarilo); alquilo; cicloalquilo; heterocicloalquilo; arilo o heteroarilo; todos opcionalmente sustituidos.
CR20110031A 2008-07-18 2011-01-17 NUEVOS DERIVADOS DE IMIDAZO [1,2-a]PIRIMIDINA, SU PROCEDIMIENTO DE PREPARACIÓN, SU APLICACIÓN COMO MEDICAMENTOS, COMPOSICIONES FARMACÉUTICAS Y NUEVA UTILIZACIÓN PARTICULARMENTE COMO INHIBIDORES DE MET CR20110031A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0804086A FR2933982A1 (fr) 2008-07-18 2008-07-18 Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met

Publications (1)

Publication Number Publication Date
CR20110031A true CR20110031A (es) 2011-03-14

Family

ID=40352183

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110031A CR20110031A (es) 2008-07-18 2011-01-17 NUEVOS DERIVADOS DE IMIDAZO [1,2-a]PIRIMIDINA, SU PROCEDIMIENTO DE PREPARACIÓN, SU APLICACIÓN COMO MEDICAMENTOS, COMPOSICIONES FARMACÉUTICAS Y NUEVA UTILIZACIÓN PARTICULARMENTE COMO INHIBIDORES DE MET

Country Status (26)

Country Link
US (1) US20110263593A1 (es)
EP (1) EP2318414A2 (es)
JP (1) JP2011528339A (es)
KR (1) KR20110043680A (es)
CN (1) CN102159577A (es)
AR (1) AR072820A1 (es)
AU (1) AU2009272518A1 (es)
BR (1) BRPI0915920A2 (es)
CA (1) CA2730964A1 (es)
CL (1) CL2011000118A1 (es)
CO (1) CO6341634A2 (es)
CR (1) CR20110031A (es)
DO (1) DOP2011000019A (es)
EA (1) EA201170224A1 (es)
EC (1) ECSP11010765A (es)
FR (1) FR2933982A1 (es)
IL (1) IL210708A0 (es)
MA (1) MA32564B1 (es)
MX (1) MX2011000670A (es)
NI (1) NI201100020A (es)
PE (1) PE20110584A1 (es)
SV (1) SV2011003811A (es)
TW (1) TW201011025A (es)
UY (1) UY31998A (es)
WO (1) WO2010007318A2 (es)
ZA (1) ZA201100428B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CA2789950C (en) 2010-02-18 2018-09-04 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
WO2011121223A1 (fr) 2010-03-30 2011-10-06 Sanofi-Aventis Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met
CN102796103A (zh) * 2011-05-23 2012-11-28 南京英派药业有限公司 6-(芳基甲酰)咪唑并[1,2-a]嘧啶和6-(芳基甲酰)[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
KR102775718B1 (ko) 2017-11-14 2025-03-06 칠드런'즈 메디컬 센터 코포레이션 인간 면역 반응을 조정하기 위한 이미다조피리미딘의 용도
KR102740831B1 (ko) * 2017-11-14 2024-12-11 칠드런'즈 메디컬 센터 코포레이션 신규 이미다조피리미딘 화합물 및 그의 용도
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2025212515A1 (en) * 2024-04-04 2025-10-09 The Board Of Trustees Of The Leland Stanford Junior University Agents for use in the treatment of endoplasmic stress

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2785157A (en) * 1952-11-05 1957-03-12 Eastman Kodak Co Benzothiazoleazoaniline compounds
JP2002507996A (ja) * 1997-07-03 2002-03-12 デュポン ファーマシューティカルズ カンパニー 神経学的障害を治療するためのイミダゾピリミジン類およびイミダゾピリジン類
US6528510B1 (en) * 1998-09-11 2003-03-04 Warner-Lambert Company HIV protease inhibitors
PL357099A1 (en) * 2000-02-07 2004-07-12 Abbott Gmbh & Co.Kg 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
US7626030B2 (en) * 2004-01-23 2009-12-01 Amgen Inc. Compounds and methods of use
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
EP1674466A1 (en) * 2004-12-27 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors
GEP20125658B (en) * 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors

Also Published As

Publication number Publication date
WO2010007318A2 (fr) 2010-01-21
SV2011003811A (es) 2011-04-29
MX2011000670A (es) 2011-04-11
ZA201100428B (en) 2012-03-28
ECSP11010765A (es) 2011-02-28
NI201100020A (es) 2011-07-21
EP2318414A2 (fr) 2011-05-11
KR20110043680A (ko) 2011-04-27
IL210708A0 (en) 2011-03-31
US20110263593A1 (en) 2011-10-27
JP2011528339A (ja) 2011-11-17
CL2011000118A1 (es) 2011-07-15
DOP2011000019A (es) 2011-02-15
AU2009272518A1 (en) 2010-01-21
MA32564B1 (fr) 2011-08-01
CN102159577A (zh) 2011-08-17
CA2730964A1 (fr) 2010-01-21
UY31998A (es) 2010-02-26
EA201170224A1 (ru) 2011-08-30
BRPI0915920A2 (pt) 2018-07-10
WO2010007318A3 (fr) 2010-04-08
CO6341634A2 (es) 2011-11-21
FR2933982A1 (fr) 2010-01-22
AR072820A1 (es) 2010-09-22
PE20110584A1 (es) 2011-09-10
TW201011025A (en) 2010-03-16

Similar Documents

Publication Publication Date Title
ECSP11010765A (es) NUEVOS DERIVADOS DE IMIDAZO[1,2-a]PIRIMIDINA, SU PROCEDIMIENTO DE PREPARACIÓN, SU APLICACIÓN COMO MEDICAMENTOS, COMPOSICIONES FARMACÉUTICAS Y NUEVA UTILIZACIÓN PARTICULARMENTE COMO INHIBIDORES DE MET
CO6331467A2 (es) Nuevos derivados de imidazo(1,2-a)piridina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion particularmente como inhibidores de met
CO6331463A2 (es) Nuevos derivados de triazolo(4,3-a)piridina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion particularmente como inhibidores de met
BRPI0814065B8 (pt) derivados de alcoóis de 1-fenil-2-piridinil alquila como inibidores da fosfodiesterase
CR11252A (es) Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met
UY31046A1 (es) Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones
EA201201663A1 (ru) Производные 2-(ариламино)-3н-имидазо[4,5-b]пиридин-6-карбоксамида и их применение в качестве ингибиторов mpges-1
EA201170772A1 (ru) Органические соединения
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
UY30824A1 (es) Nuevos derivados de idazolil éster o amida, composiciones farmacéuticas conteniéndolas, procesos de preparacion y aplicaciones.
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
CY1111367T1 (el) Νεα παραγωγα της διοσμετινης, η μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα περιεχουν
MX350809B (es) Derivados nucleósidos con sustitución 2',4'-difluoro-2'-metilo como inhibidores de la replicación del arn del vhc.
CY1109637T1 (el) Νεα τρικυκλικα παραγωγα, η μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα περιεχουν
CL2013003056A1 (es) Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas.
NI201000134A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
UY32753A (es) NUEVOS DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA, SU PREPARACIÓN Y SU UTILIZACIÓN EN FARMACÉUTICA
UY30865A1 (es) Nuevos analogos de piridina x 161
UY29510A1 (es) Derivados de urea, metodos para su fabricación, y usos de los mismos
UY30868A1 (es) Nuevos compuestos de piridina, composiciones farmacéuticas conteniéndolas y aplicaciones.
UY33927A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
TW200745048A (en) Novel benzimidazole and benzothiazole derivatives, preparation process therefor, application thereof as medicaments, pharmaceutical compositions and novel use especially as CMET inhibitors
NI201000111A (es) Nuevos derivados de acido 2-mercaptociclopentanocarboxilico, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
CU20130037A7 (es) Nuevos derivados dihidrobenzoxatiazepinas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ECSP10010412A (es) Compuesto (r)-n*6*-etil-6,7-dihidro-5h-indeno(5,6-d)tiazol-2,6-diamina y su uso como antipsicótico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)